Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification
Neuro-Oncology Practice · 26.12.2025 · 12 (6) · 1030-1039
DOI: 10.1093/nop/npaf067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 11.07.2025. Verfasst von Jasmin Jo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology Oncology, East Carolina University. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The incorporation of molecular parameters into WHO CNS5 has led to reclassification of gliomas. We describe presenting clinical and radiographic features of diffuse adult gliomas according to CNS5 category.
Methods
We reviewed pathology reports, clinical and MRI data at presentation of 972 adult patients with glioma between January 2010 and February 2022. Continuous variables were presented as median; categorical variables as numbers and percentages. Comparison was performed using Fisher’s exact test.
Results
Seven hundred and thirty-six patients had sufficient data for CNS5 reclassification: Grade 2 IDH mutant (IDHmut) astrocytoma (A2) n = 69, grade 3 IDHmut astrocytoma (A3) n = 37, grade 4 IDHmut astrocytoma (A4), n = 32, grade 2 oligodendroglioma (O2) n = 60, grade 3 oligodendroglioma (O3) n = 23, and IDH-wildtype glioblastoma (GBM) n = 515. Age at presentation differed between grades 2 and 3 gliomas and grade 4 (mean age: 39 vs 61.7; P < .001); A4 were younger than GBM (39.8 vs 63.1). Seizure was more common in IDHmut gliomas than GBM (58.4% vs 31.8%; P < .001); cognitive impairment was more common in GBM than in IDHmut gliomas (64.4% vs 34.4%; P < .001) and A4 (64% vs 40.6%; P = 0.013). Focal deficits were more frequent in GBM than IDHmut gliomas (74.2% vs 30.5%; P < .001). Contrast enhancement was more frequent in GBM than IDHmut gliomas (93% vs 48%; P < .001), similar with A4 (93% vs 96%; P = 1.00). Minimum apparent diffusion coefficient was higher in IDHmut glioma than GBM (P < .001). Calcification was more common in oligodendroglioma than astrocytoma and GBM (P < .001).
Conclusion
Significant differences in the clinical and radiographic features exist among CNS5 glioma subtypes, informing potential diagnosis, management and prognosis at initial presentation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology Oncology, East Carolina University.
- Department of Neurology, Division of Neuro-oncology, University of Virginia, Charlottesville, Virginia.
- School of Medicine, University of Virginia.
- Department of Public Health Sciences, University of Virginia.
- Department of Radiology, University of Virginia, Charlottesville, Virginia.
- Department of Pathology, Division of Neuropathology, University of Virginia, Charlottesville, Virginia.
ORCID-Profile: Jasmin Jo, David Schiff
Zitieren
APA
Jo, J., Mondia, M. W. L., Arewa, J., How, A., Patrie, J., Dueck, N., Gilbow, R., Goschka, A., Joyner, D., Patel, S. H., Lopes, M. B., & Schiff, D. (2025). Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification. Neuro-Oncology Practice, 12(6), 1030-1039. https://doi.org/10.1093/nop/npaf067
Vancouver
Jo J, Mondia MWL, Arewa J, How A, Patrie J, Dueck N, et al. Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification. Neuro-Oncology Practice. 2025;12(6):1030-1039. doi:10.1093/nop/npaf067
BibTeX
@article{Jo2025,
author = {Jo, Jasmin and Mondia, Mark Willy L and Arewa, Josephine and How, Andrew and Patrie, James and Dueck, Nicholas and Gilbow, Reed and Goschka, Andrew and Joyner, David and Patel, Sohil H and Lopes, M Beatriz and Schiff, David},
title = {Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification},
journal = {Neuro-Oncology Practice},
year = {2025},
volume = {12},
number = {6},
pages = {1030--1039},
doi = {10.1093/nop/npaf067}
}
EUVIMED